文献速递神经肿瘤

治疗对继发性胶质母细胞瘤患者生存的影响

Impact of treatment on survival of patients with secondary glioblastoma.
PubMed 文献 · J Neurooncol · 2017-05-30

本研究纳入2004至2015年间39例由既往治疗过的WHO II或III级肿瘤演变而来的继发性胶质母细胞瘤患者,评估手术切除范围与辅助治疗对生存的影响。全组中位生存期为11个月,未实现全切除、术后KPS差及未接受辅助治疗与更短生存相关。作者认为,在经选择的患者中,完全切除和辅助治疗可能延长生存。

要点

  • 39例继发性胶质母细胞瘤患者中,全切除造影强化病灶者19例(48.7%)。
  • 全组中位生存期11个月(范围1-35)。
  • 未全切除、术后KPS差及未辅助治疗与更短生存相关。

核心结论

  • 在经选择的患者中,完全切除和辅助治疗可能延长生存,尽管既往已接受多次治疗。
  • 未实现全切除、术后KPS差及未接受辅助治疗是单变量分析中更短生存的预后因素(p<0.0001、p=0.028和p=0.003)。
  • 自初始诊断以来的时间和既往治疗与胶质母细胞瘤后的生存无关。

研究设计与样本

  • 纳入2004至2015年间39例由既往治疗过的低级别胶质瘤演变而来的继发性胶质母细胞瘤患者。
  • 评估切除范围、病理参数、辅助治疗以及恶性转化后的生存。
  • 原发肿瘤级别为WHO II级16例(41.0%),WHO III级23例(59.0%)。
  • 中位年龄43岁(范围23-67),术前中位KPS 80(范围60-100),术后中位KPS 70(范围50-100)。

主要发现

  • 全切除造影强化病灶者19例(48.7%)。
  • 辅助治疗为放化疗23例(59.0%)、放疗3例(7.7%)、化疗5例(12.8%)、无辅助治疗8例(20.5%)。
  • 全组中位生存期11个月(范围1-35)。
  • 单变量分析中,未实现全切除、术后KPS差及未接受辅助治疗与更短生存相关(p<0.0001、p=0.028和p=0.003)。
  • 自初始诊断以来的时间和既往治疗与胶质母细胞瘤后的生存无关。

临床怎么用

  • 作者认为,在经选择的患者中,完全切除和辅助治疗可能延长生存,尽管既往已接受多次治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Data concerning treatment of secondary glioblastoma evolving from previously treated WHO II or III grade tumors are very scarce. The aim of this study was to evaluate the impact of surgical resection and adjuvant treatment on survival in patients with secondary glioblastoma. Thirty-nine patients with secondary glioblastoma evolving from previously treated lower grade gliomas between 2004 and 2015 were included. We evaluated the extent of resection, pathological parameters, adjuvant treatment, as well as survival after malignant transformation. The primary tumor grade was WHO II in 16 (41.0%) and WHO III in 23 (59.0%) patients. Median age was 43 years (range 23-67). Median KPS was 80 (range 60-100) before surgery, and 70 (range 50-100) after surgery. Gross total resection (GTR) of contrast-enhancing disease was achieved in 19 (48.7%) patients. Adjuvant treatment was radio-chemotherapy in 23 (59.0%), radiotherapy in three (7.7%), chemotherapy in five (12.8%) and none in eight (20.5%) patients. Median survival was 11 months (range 1-35) in the entire group. Time since initial diagnosis and previous treatment did not correlate with survival after glioblastoma. Failed GTR, poor KPS after surgery, and no adjuvant treatment were prognostic factors for shorter survival in univariate analysis (p < 0.0001, p = 0.028 and p = 0.003). In selected patients, complete resection and adjuvant treatment may prolong survival in spite of multiple previous therapies.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Hamisch C, Ruge M, Kellermann S, et al. Impact of treatment on survival of patients with secondary glioblastoma. J Neurooncol. 2017. PMID: 28560660. doi:10.1007/s11060-017-2415-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。